Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Storer

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Bioorganic & Medicinal Chemistry Letters|January 4, 2011
Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinenceMark D Andrews, Paul V Fish, Julian Blagg, et al.
Journal of Medicinal Chemistry|June 21, 2023
Discovery and Optimization of the First ATP Competitive Type-III c-MET InhibitorIacovos N Michaelides, Gavin W Collie, Ulf Börjesson, et al.
Plos One|April 7, 2016
Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic ReleaseAristos J Alexandrou, Adam R Brown, Mark L Chapman, et al.
Journal of Medicinal Chemistry|July 7, 2017
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na<sub>V</sub>1.7Nigel A Swain, Dave Batchelor, Serge Beaudoin, et al.
Nature Communications|March 25, 2026
A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degraderMonica C Rodrigo-Brenni, Jasper C Komen, Ghaith M Hamza, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Bioorganic & Medicinal Chemistry Letters|January 4, 2011
Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinenceMark D Andrews, Paul V Fish, Julian Blagg, et al.
Journal of Medicinal Chemistry|June 21, 2023
Discovery and Optimization of the First ATP Competitive Type-III c-MET InhibitorIacovos N Michaelides, Gavin W Collie, Ulf Börjesson, et al.
Plos One|April 7, 2016
Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic ReleaseAristos J Alexandrou, Adam R Brown, Mark L Chapman, et al.
Journal of Medicinal Chemistry|July 7, 2017
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na<sub>V</sub>1.7Nigel A Swain, Dave Batchelor, Serge Beaudoin, et al.
Nature Communications|March 25, 2026
A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degraderMonica C Rodrigo-Brenni, Jasper C Komen, Ghaith M Hamza, et al.
Pageof 5